News

MDS Nordion, a provider of medical isotopes and radiopharmaceuticals, has announced that it has commenced the manufacture of CardioGen-82 (Rubidium-82 generators), for Bracco. MDS Nordion has designed and

AEterna Zentaris has initiated an extended study in the Phase-III program with cetrorelix pamoate, for the treatment of benign prostatic hyperplasia (BPH). Cetrorelix pamoate is currently in three

Metabasis and its partner Merck have announced that AMP protein kinase (AMPK) activators, has yielded a lead candidate that Merck has selected to advance into late preclinical development.

Osteotech has announced that it has completed enrollment for the clinical trial of DuraTech BioRegeneration Matrix. DuraTech, used to repair dura mater during cranial surgical procedures, is based

FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) voted that Zyprexa (olanzapine), an atypical antipsychotic, is effective and acceptably safe for the acute treatment of schizophrenia or manic or mixed

“Following the Annual General Meeting of the Company yesterday, the Board is pleased to recognize Livleen for her outstanding financial leadership in the first half of 2009,” said

InteKrin has declared Phase 2a clinical study results at the American Diabetes Association annual meeting in New Orleans. The study demonstrated that once a day oral treatment with

Transdel Pharmaceuticals and JH Direct have entered into a licensing agreement, providing JH Direct with the exclusive worldwide rights to Transdel’s anti-cellulite cosmeceutical product. Under the agreement, JH

Bio-Bridge Science has declared that its wholly-owned subsidiary, Bio-Bridge Science has entered into a joint venture contract with JR Scientific to form a new cell culture medium joint